Stockreport

ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with...

ProMIS Neurosciences Inc. - Common Shares  (PMN) 
PDF Cross-trial analysis supports plasma pTau as a potential early predictor of clinical benefit, reinforcing the biomarker-driven design of ProMIS’ PRECISE-AD trial ProMI [Read more]